Is Forte Biosciences Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Forte Biosciences Inc (FBRX) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Forte Biosciences Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Forte Biosciences Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Forte Biosciences Inc?

Muslim investors may consider investing in Forte Biosciences Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Forte Biosciences Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Forte Biosciences Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Forte Biosciences Inc updated?

The Shariah compliance status of Forte Biosciences Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Forte Biosciences Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Forte Biosciences Inc?

You can check the latest Shariah compliance status of Forte Biosciences Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

FBRX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 03, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Forte Biosciences Inc (FBRX)

Based on 12 analysts giving stock ratings to Forte Biosciences Inc in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Forte Biosciences Inc. Stock Analysis FBRX

United States Health Care Small Cap Report: 2025 Annual

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The company is headquartered in Dallas, Texas and currently employs 19 full-time employees. The company went IPO on 2017-04-13. The company is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The firm's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.

Key Statistics of Forte Biosciences Inc (FBRX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$21.60$24.00

Today's Open

$23.26

Volume

177.69K

P/E Ratio (TTM)

52 Week Range

$7.00$35.80

Market Cap

534.76M

Avg. Volume

221.55K

Dividend Yield

Financial Metrics & Statements of Forte Biosciences Inc (FBRX)

FAQ's for Forte Biosciences Inc (FBRX)

According to Musaffa’s Shariah screening methodology, Forte Biosciences Inc (FBRX) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.